Venus Concept

VERO

Market cap $4.33M

Overview Fund Activity

2.33 USD

+0.01

0.43%

At close Updated Sep 12, 4:00 PM EDT

1 day

0.43%

5 days

3.1%

1 month

-5.28%

3 months

-8.98%

6 months

-18.82%

Year to date

-46.19%

1 year

-62.18%

5 years

-99.42%

10 years

-99.99%

About: Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.

Employees: 292

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

11% less funds holding

Funds holding: 9 [Q1] → 8 (-1) [Q2]

11.13% less ownership

Funds ownership: 16.68% [Q1] → 5.54% (-11.13%) [Q2]

20% less capital invested

Capital invested by funds: $307K [Q1] → $244K (-$62.8K) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Financial journalist opinion

Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript

Venus Concept Inc. (NASDAQ:VERO ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Domenic Della Penna - Executive VP & CFO Rajiv Kanishka Liyanaarchchie De Silva - CEO & Director Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2025 Earnings Conference Call for Venus Concept Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward- looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K filed with the Securities and Exchange Commission.

Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript

Venus Concept Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025.

Venus Concept Announces Second Quarter 2025 Financial Results

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025.

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction

Further reduction of outstanding debt by Madryn Asset Management improves the Company's balance sheet position Further reduction of outstanding debt by Madryn Asset Management improves the Company's balance sheet position

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction

Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd (“Meta Healthcare Group”) in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives.

Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript

Venus Concept Inc. (NASDAQ:VERO ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Rajiv De Silva - CEO Domenic Della Penna - CFO Conference Call Participants Thomas McGovern - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2025 Earnings Conference Call for Venus Concept Inc. At this time all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay.

Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript

Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share.

Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 14, 2025, subject to the satisfaction of customary closing conditions.

Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

See News Rankings

Charts implemented using Lightweight Charts™